Pathology: mHNSCC - L1 - all population;
| mHNSCC - L1 - all population | |||
| KEYNOTE-048 (P vs C ; all population), 2019 | KEYNOTE-048 (PC vs C ; all population), 2019 | ||
| pembrolizumab alone | 1 | T1 | |
| pembrolizumab plus 5FU plus platin | 1 | T1 | |
| cetuximab plus platin plus 5FU | 0 | T0 | T0 |